
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc. demonstrates a promising outlook due to the positive clinical response trends observed in their key pipeline product, icotrokinra, which showed a 5-7% improvement in clinical response from week 12 to 28, indicating robust long-term efficacy. Additionally, the data reveals significant endoscopic improvement rates and high levels of disease clearance in difficult-to-treat areas, setting a strong foundation for market uptake upon its anticipated launch following the NDA submission in July 2025. Furthermore, the company's established track record in business development and expected momentum through key catalysts in 2025 reinforces a favorable position for continued growth and advancement within the biopharmaceutical market.
Bears say
Protagonist Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, highlighted by concerns regarding potential safety issues in ongoing clinical trials and the possibility that strategic partners may refrain from further developing its key product icotrokinra, due to competitive pressures. Additionally, the company is exposed to heightened regulatory and pricing risks, particularly given the evolving landscape in the orphan drug market, which may impact future profitability and market access. Coupled with these factors is the looming threat of dilution stemming from future cash needs, which could further impact shareholder value in the volatile biopharmaceutical sector.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares